id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2333-0005,FDA,FDA-2020-E-2333,Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION,Notice,Determinations,2022-07-08T04:00:00Z,2022,7,2022-07-08T04:00:00Z,2022-09-07T03:59:59Z,2023-11-17T21:08:02Z,2022-14546,0,0,09000064851b6d71
FDA-2020-E-2333-0004,FDA,FDA-2020-E-2333,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2022-06-14T04:00:00Z,2022,6,2022-06-14T04:00:00Z,,2022-06-14T16:48:50Z,,0,0,0900006485162e1f